Findings

What do systematic reviews say?

4,771 questions · 10,185 findings · 893 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2,109 · 20.7%GRADE not reported 1,125 · 11%Very low 2,279 · 22.4%Low 2,514 · 24.7%Moderate 1,709 · 16.8%High 449 · 4.4%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Intervention not reported

Serious adverse events · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Progression‐free survival (PFS) ‐ Network (subnet 1) included 11 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 2908 participants
GRADE not reported

Intervention not reported

Adverse events (grade 3 or 4) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

MSKCC risk groups · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Overall survival (OS) ‐ Network included 15 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 3937 participants
GRADE not reported

Intervention not reported

Quality of life (QoL) · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Progression‐free survival (PFS) ‐ Network (subnet 1) included 10 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and an intermediate or poor risk according to the International…

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1522 participants
GRADE not reported

Intervention not reported

IMDC risk group · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Overall survival (OS) ‐ Network (subnet 1) included 5 pairwise comparisons ‐ Median · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 933 participants
GRADE not reported

Intervention not reported

Serious adverse events · people with a confirmed diagnosis of advanced renal cell carcinoma (RCC) and a favourable risk according to the International Metastatic…

The review found no eligible studies for this question.

1 finding from 1 review

First‐line therapy for adults with advanced renal cell carcinoma: a systematic review and network meta‐analysis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Sildenafil vs IV nitroglycerin

All‐cause mortality · pregnant women with fetal growth restriction

1 finding from 1 review

Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Sildenafil vs IV nitroglycerin

Fetal mortality · pregnant women with fetal growth restriction

1 finding from 1 review

Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

Sildenafil vs IV nitroglycerin

Neonatal mortality · pregnant women with fetal growth restriction

1 finding from 1 review

Interventions affecting the nitric oxide pathway versus placebo or no therapy for fetal growth restriction in pregnancy 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 23 participants
Low

CBT interventions (CBT with and without exercise) vs control (standard care or sham treatments)

FoF (immediate postintervention)a · older adults (mean age minus 1 standard deviation is more than 60 years)

1 finding from 1 review

Cognitive behavioural therapy (CBT) with and without exercise to reduce fear of falling in older people living in the… 2023 · Cochrane Headline outcomes only
no estimate extracted
11 studies · 2357 participants
Moderate

CBT interventions (CBT with and without exercise) vs control (standard care or sham treatments)

FoF (sustainability of effects, up to 6 months' postintervention) · older adults (mean age minus 1 standard deviation is more than 60 years)

1 finding from 1 review

Cognitive behavioural therapy (CBT) with and without exercise to reduce fear of falling in older people living in the… 2023 · Cochrane Headline outcomes only
no estimate extracted
8 studies · 1784 participants
Low

CBT interventions (CBT with and without exercise) vs control (standard care or sham treatments)

FoF (sustainability of effects, > 6 months' postintervention) · older adults (mean age minus 1 standard deviation is more than 60 years)

1 finding from 1 review

Cognitive behavioural therapy (CBT) with and without exercise to reduce fear of falling in older people living in the… 2023 · Cochrane Headline outcomes only
no estimate extracted
5 studies · 1185 participants
Moderate

CBT interventions (CBT with and without exercise) vs control (standard care or sham treatments)

Activity avoidance · older adults (mean age minus 1 standard deviation is more than 60 years)

1 finding from 1 review

Cognitive behavioural therapy (CBT) with and without exercise to reduce fear of falling in older people living in the… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 312 participants
Low

CBT interventions (CBT with and without exercise) vs control (standard care or sham treatments)

Falls · older adults (mean age minus 1 standard deviation is more than 60 years)

It is very uncertain whether CBT interventions (CBT with and without exercise) changes occurrence of falls compared with control (standard care or sham treatments) (very low certainty).

1 finding from 1 review

Cognitive behavioural therapy (CBT) with and without exercise to reduce fear of falling in older people living in the… 2023 · Cochrane Headline outcomes only
RR 0.96 [0.66, 1.39]
5 studies · 1119 participants
Very low

CBT interventions (CBT with and without exercise) vs control (standard care or sham treatments)

Depression · older adults (mean age minus 1 standard deviation is more than 60 years)

1 finding from 1 review

Cognitive behavioural therapy (CBT) with and without exercise to reduce fear of falling in older people living in the… 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 314 participants
Low

CBT interventions (CBT with and without exercise) vs control (standard care or sham treatments)

Adverse effects · older adults (mean age minus 1 standard deviation is more than 60 years)

The review found no eligible studies for this question.

1 finding from 1 review

Cognitive behavioural therapy (CBT) with and without exercise to reduce fear of falling in older people living in the… 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found